News

The Neurodegeneration Medicines Acceleration Program (Neuro-MAP) led by MRC Technology is a non-profit organization that brings together promising drug projects for brain diseases like Parkinson’s and Alzheimer’s that have stalled due to lack of support with funding organizations. Their goal is to revive these projects by helping scientists continue their…

A new study is now enrolling and accepting volunteers to investigate the potential of a new drug to slow the devastating effects of Alzheimer’s disease on patients’ memory and physical activity. Eligible participants include men and women with ages between 55 to 85 years old suffering from mild to severe Alzheimer’s.

Scientists at the University of Illinois have created an exciting new method for examining how proteins change their shape right inside cells, using fluorescent markers and a specialized microscope. They recently published their work in the December 1st issue of the journal Public Library of Science One (PLoS…

Recently, a new study presented at the Annual Meeting of the Radiological Society of North America (RSNA) showed that in brains of patients affected with Alzheimer’s disease, changes in brain connections can be visualized by Magnetic resonance imaging (MRI). Alzheimer’s disease is currently estimated to affect approximately 5 million…

A drug that is usually used for treatment of psoriasis has been found to stimulate the activity of the enzyme ADAM10 in the brain of Alzheimer’s patients (AD), providing encouraging results for treating the disease. The study, which was recently published in the journal Neurology, entitled “…

A new study published this week in the Journal of Neuroscience suggests a potential therapy for a type of neurotransmitter receptor for Frontotemporal Dementia. The study entitled ”Tau-Mediated NMDA Receptor Impairment Underlies Dysfunction of a Selectively Vulnerable Network in a Mouse Model of Frontotemporal Dementia,” was…